Course Details
- Discussion on the burden of SSc-ILD. It’s variable and unpredictable nature.
- The clinical meaningfulness and early treatment of SSc-ILD with nintedanib.
- How to screen and monitor patients in the context of IPF, other fibrosing ILDs with a progressive phenotype, and SSc-ILD.